Clinical Trials are a core service at PC-TRiADD and are conducted in close partnership with the BC Cancer Agency, national and international clinical trials networks, and industry partners. These networks serve to enhance enrollment in our clinical trials, while the structure of the Canadian medical system and centralized treatment centres such as ours mean that patient follow-up information is closely tracked.
By combining the genitourinary research programs at the Vancouver Prostate Centre and the BC Cancer Agency, clinical trial patients can participate in a full range of investigational studies. Last year PC-TRiADD initiated 15 new clinical trials.
Our networks have performed numerous co-operative group and industry-sponsored trials, involving well-known pharmaceutical and biotech companies. In addition, this group has sponsored clinical trial submissions to Health Canada and has been successfully audited by regulatory agencies including Health Canada and US FDA.
Clinical trials are also supported by our CLIA-certified and CAP-accredited Clinical Assay Laboratory, which specializes in enumeration of Circulating Tumor Cells (CTCs) by using the CellSearch® Platform (Janssen Diagnostics). Circulating tumour cells are cancer cells that have detached from the main tumour before entering the bloodstream. This cell type represents an important transition in cancer transformation and metastasis, and portends significant clinical impact in diagnosis, prognosis, treatment, and monitoring. Our Clinical Assay Laboratory also performs traditional single analyte ELISA assays as well as multiplex assays utilizing the Bio-Plex system, which enables the detection and quantification of multiple analytes (proteins, peptides, and nucleic acids) in a single sample volume.